Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company committed to merging traditional therapeutics with psychedelic research to address a variety of underserved conditions. The company's focus spans post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
Silo's mission is to identify and license transformative assets, funding cutting-edge research to enhance patient well-being and advance the healthcare industry. Recent achievements include the filing of a provisional patent for SP-26, a ketamine-based implant for chronic pain management, and the exclusive licensing of SPC-15 from Columbia University, a novel intranasal treatment for PTSD and anxiety.
Core Business and Projects
- SPC-15: An intranasal treatment targeting PTSD and stress-induced anxiety disorders. Silo has exercised its option to license SPC-15 from Columbia University, with preclinical studies showing promising results.
- SP-26: A time-release, ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. The implant has shown positive results in pre-clinical studies and is expected to be the first at-home approved ketamine-based therapeutic if it passes clinical trials.
- SPC-14: An intranasal compound for the treatment of Alzheimer's disease, showing potential in preclinical studies for improving cognitive function and stress reduction.
- SPU-16: A CNS-homing peptide targeting multiple sclerosis (MS), developed in collaboration with the University of Maryland, Baltimore.
Silo's innovative approach combines traditional therapies with psychedelic treatments, aiming to develop novel formulations and drug delivery systems. The company's robust pipeline and strategic partnerships with leading medical universities position Silo at the forefront of biopharmaceutical advancements.
Financial Condition and Partnerships
Silo Pharma collaborates extensively with Columbia University and the University of Maryland, Baltimore, providing essential financial resources to advance their research from the clinical stage to commercialization. The company is financially positioned to support ongoing and future projects that could significantly impact the medical and psychedelic treatment landscape.
For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Silo Pharma, Inc. (OTCQB: SILO) has entered a Scientific Research Agreement with the University of California San Francisco (UCSF) to explore the effects of psilocybin on inflammatory markers in patients with Parkinson's, Bipolar disorder, and chronic back pain. This agreement will utilize four other planned clinical trials by UCSF. CEO Eric Weisblum emphasized the potential of psilocybin to reduce inflammation related to these conditions, which may improve treatment outcomes. The study will be conducted at UCSF's Translational Psychedelic Research Program, focusing on the impact of psychedelics on various disorders.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its initial application to list on the NASDAQ Capital Market. This follows the board's prior approval to commence the up-listing process. The NASDAQ listing is contingent upon meeting regulatory requirements and acceptance by NASDAQ, which cannot be assured. CEO Eric Weisblum emphasized that a NASDAQ listing aims to enhance investor liquidity, attract institutional investors, and improve the company's visibility. Silo Pharma focuses on developing psychedelic therapies for conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its investigator-led study using Psilocybin for treating Parkinson’s disease for ethics board review in the Netherlands. CEO Eric Weisblum expressed satisfaction with this milestone and anticipates sharing more details with the scientific community and shareholders.
Silo Pharma is focused on merging traditional therapeutics with psychedelic research to assist patients suffering from conditions like depression, PTSD, and rare neurological disorders.
Silo Pharma (OTCQB: SILO) has announced a joint venture with Zylo Therapeutics to develop a sustained-release topical delivery system for ketamine and psilocybin. This collaboration aims to address the needs of patients with dysphagia, particularly those dealing with Alzheimer’s and Parkinson’s diseases. The ZTI’s Z-pod technology will enable the controlled delivery of these psychedelics, potentially reducing hallucinogenic effects while exploring their safety and efficacy. This initiative aligns with Silo Pharma's mission to innovate therapeutic solutions.
Silo Pharma, Inc. (OTCQB: SILO) announced its Board of Directors' unanimous decision to uplist to the NASDAQ. CEO Eric Weisblum emphasized that this move aims to enhance visibility and attract institutional investors, fostering long-term shareholder value. The uplisting is contingent upon meeting NASDAQ's listing requirements and securing approval. Silo Pharma focuses on developing psilocybin-based therapeutics for mental health issues and neurological disorders.
Silo Pharma, Inc. (OTCQB: SILO), a biopharmaceutical company focusing on psilocybin therapy, has finalized a sublicense agreement related to its provisional patent for CNS homing peptides aimed at treating pain from neuroinflammation in cancer patients. CEO Eric Weisblum expressed enthusiasm for the collaboration and emphasized the company's commitment to creating shareholder value while developing innovative therapeutics. The news comes on the heels of an earlier Letter of Intent from February, highlighting Silo's strategic growth.
Silo Pharma has entered an exclusive option agreement with the University of Maryland to investigate novel joint-homing peptides aimed at treating inflammation related to autoimmune diseases, specifically rheumatoid arthritis. These peptides could enhance drug delivery directly to affected joints, potentially increasing therapeutic efficacy while minimizing systemic toxicity. Silo's CEO emphasized the potential of this technology as a revolutionary drug delivery platform that meets the need for innovative treatments for patients with rare diseases.
Silo Pharma, a biopharmaceutical company, announced that CEO Eric Weisblum will present at Proactive's One2One Virtual Investor Forum on February 23, 2021, at 1 p.m. EST. The event is expected to reach Proactive's 20,000 YouTube subscribers and will be broadcasted globally. Silo Pharma focuses on merging traditional therapeutics with psychedelic research to address conditions such as depression, PTSD, and Parkinson's disease. The presentation will include a Q&A session and will be made available online after the event.
Silo Pharma has signed a Master License Agreement with the University of Maryland Baltimore to license innovative Central nervous system-homing peptides aimed at treating multiple sclerosis and other neuroinflammatory disorders. This agreement follows preclinical studies that support the peptide's efficacy. CEO Eric Weisblum emphasized Silo's commitment to merging traditional therapeutics with psychedelic research, suggesting potential benefits for patients with neurological conditions.
Silo Pharma, a developmental stage biopharmaceutical company, has secured $4.275 million through Securities Purchase Agreements for its Series C Preferred Stock. The financing involves issuing 4,276 shares and warrants for 14,253,333 shares of common stock with an exercise price of $0.30 per share. The funds will support the development of psychedelic therapeutics for conditions like depression and PTSD. The transaction, expected to close by February 11, 2021, reflects investor confidence in Silo's strategic growth plan.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What does Silo Pharma, Inc. specialize in?
What are Silo Pharma's leading development programs?
Who are Silo Pharma's research partners?
What recent achievements has Silo Pharma announced?
How does Silo Pharma aim to impact the healthcare industry?
Where can I find more information about Silo Pharma?
What is the significance of Silo Pharma's SP-26 program?
What progress has been made with the SPC-15 program?
What conditions does Silo Pharma aim to address with its treatments?
How does Silo Pharma fund its research projects?
